The biotech industry needs to pay more attention to women’s health
Even as new forms of contraception, fertility treatments, and therapies for vaginal health are emerging, there is a dearth of investment in women’s health. Despite a slew of initial public offerings and new players, including Agile, Daré, Juniper, Myovant, and ObsEva over the past few years, women’s biotech isn’t yet on everyone’s radar. Per capita spending…
Utah Standard News depends on the support of readers like you.
Good Journalism requires time, expertise, passion and money. We know you appreciate the coverage here. Please help us to continue as an alternative news website by becoming a subscriber or making a donation. To learn more about our subscription options or make a donation, click here.
To Advertise on UtahStandardNews.com, please contact us at: ed@utahstandardnews.com.
Comments - No Responses to “The biotech industry needs to pay more attention to women’s health”
Sure is empty down here...